First-in-human phase i study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors
- Meulendijks, D.
- Jacob, W.
- Martinez-Garcia, M.
- Taus, A.
- Lolkema, M.P.
- Voest, E.E.
- Langenberg, M.H.G.
- Kanonnikoff, T.F.
- Cervantes, A.
- De Jonge, M.J.
- Sleijfer, S.
- Soerensen, M.M.
- Thomas, M.
- Ceppi, M.
- Meneses-Lorente, G.
- James, I.
- Adessi, C.
- Michielin, F.
- Abiraj, K.
- Bossenmaier, B.
- Schellens, J.H.M.
- Weisser, M.
- Lassen, U.N.
ISSN: 1557-3265, 1078-0432
Ano de publicación: 2016
Volume: 22
Número: 4
Páxinas: 877-885
Tipo: Artigo